In a pioneering  phase 2 clinical trial published in the 'Journal of Pediatric Gastroenterology and Nutrition,' Oral Viscous Budesonide (OVB) exhibited good effective, safety, and tolerability profiles for treating pediatric patients (aged 3-18 years) with eosinophilic esophagitis after repaired esophageal atresia (EoE-EA). Renato Tambucci et al. aimed to assess the effects of OVB in EoE-EA.

This open-label, single-arm study with randomized pharmacokinetic sampling included EoE-EA sufferers. Participants received an age-appropriate dosage of OVB two times a day for 12 weeks and underwent endoscopic evaluations. The rate of volunteers achieving histological remission was the major endpoint ascertained.

Endoscopic and clinical benefits following treatment, as well as safety evaluations, were the secondary endpoints included. The study included 8 children with EA-EoE (median age 9.1 years, interquartile range 5.5). Among them, five patients were given a twice-daily dosage of 0.8 mg of OVB, while three patients received 1.0 mg. Histological remission was attained in all but one individual (87.5%).

All patients illustrated a significant improvement in their clinical scores by the conclusion of their treatment. Post-intervention, there were no endoscopic signs of EoE, and there were no treatment-related adverse events reported. Therefore, OVB (esophageal topical steroid) use is favorable for the management of pediatric patients suffering from EoE-EA.